AU2023202607B2 — Integrase inhibitors for the prevention of HIV
Assigned to Gilead Sciences Inc · Expires 2025-06-05 · 1y expired
What this patent protects
The present invention relates to a method of preventing an HIV infection in a subject, comprising administering to the subject bictegravir, or a pharmaceutically acceptable salt thereof, and optionally further administering emtricitabine, or a pharmaceutically acceptable salt t…
USPTO Abstract
The present invention relates to a method of preventing an HIV infection in a subject, comprising administering to the subject bictegravir, or a pharmaceutically acceptable salt thereof, and optionally further administering emtricitabine, or a pharmaceutically acceptable salt thereof, and tenofovir or a pharmaceutically acceptable salt thereof (especially tenofovir alafenamide hemifumarate).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.